Dr. Matthew Croughan This is Me

Education

 View all 9 references Web References

1. 1. www.cascience.org

   www.cascience.org/csta/conf_Ma - [Cached]

   Published on: 10/18/2005   Last Visited: 6/9/2008

   Matthew Croughan
   
   About Matthew Croughan
   
   At "the Keck", Professor Croughan teaches three graduate courses in bioprocessing.He also serves as faculty advisor on collaborative projects with industry (Team Masters Projects).His laboratory classes and research range from monoclonal antibody production and purification, to fermented beverages, to biodiesel production from algae.
   
   Prior to joining KGI, Dr. Croughan spent 8 years consulting with over 35 firms on biopharmaceutical process development and manufacturing issues.He still consults with many firms part-time.
   
   Prior to consulting, Dr. Croughan worked at Genentech for ten years.He led the development of the first licensed, fed-batch cell culture process, a breakthrough platform technology now used by Genentech and throughout the industry for production of high-dose therapeutic antibodies and other proteins.He has a B.S. from U.C. Berkeley and a Ph.D from M.I.T., both in chemical engineering.
   
   Matthew Croughan's Keck Graduate Institue Web Site: http://www.kgi.edu/x3039.xml

2. 2. Forum, February 25, 1999

   www.parc.xerox.com/ops/project - [Cached]

   Published on: 2/25/1999   Last Visited: 4/10/2002

   Matthew Croughan, Ph.D. Industrial Liaison, Biotechnology Process Engineering Center, M.I.T.
   
   ...
   Matt has a B.S. from U.C. Berkeley and a Ph.D from M.I.T., both in chemical engineering. He worked at Genentech for ten years and gained substantial expertise in the growth of animal cells for commercial production of pharmaceutical proteins. Matt lead the development of the commercial cell culture process for the production of Pulmozymetm and an upgrade of the commercial cell culture process for the production of Activasetm. He finished his career at Genentech as the chief scientist for the Vacaville plant, the worldUs largest and most automated cell culture manufacturing plant.
   
   Matt left Genentech in early 1998 to start a new biotechnology company in the tissue engineering field. In collaboration with professors at MIT, Harvard, and Cornell, they are developing engineered, microscale organs for partial replacement of animal testing. While the technology is in development at the universities, Matt consults part-time for various biotechnology companies and serves as the Industrial Liaison for the Biotechnology Process Engineering Center at MIT.

3. 3. FINAL PROGRAM

   www.engconfintl.org/pastconf/2 - [Cached]

   Last Visited: 2/7/2008

   , Matt Croughan, MIT